スギ花粉症に対するアイピーディ®の効果

抄録

IPD® (supratast tosilate) was investigated for its prophylactic efficacy and therapeutic efficacy in the treatment of cedar pollinosis during the 1996 cedar pollen season. The subjects investigated were patients at the Gifu University School of Medicine and its affiliated hospitals, who had a history of cedar pollinosis. The patients were classified into two treatment groups: the prophylaxis group (70 patients), in whom IPD® administration began before the start of cedar pollen dispersion, and the treatment group (49 patients), who underwent IPD® treatment only after cedar pollen dispersion had begun and symptoms of pollinosis had manifested.
Results were as follows: (1) The nasal symptoms (sneezing, runny nose, nasal congestion) were milder in the prophylaxis group than in the treatment group throughout the cedar pollen season, with the difference being significant during the season's first 2 weeks. (2) In the prophylaxis group, IPD®'s inhibitory effect was rated as excellent in 18.6% of the patients, good in 45.7% and fair in 20.0%. In the treatment group, the improvement in the symptoms was rated as disappearance in 4.2%, excellent in 20.8% and good in 43.8%. (3) When symptom inhibition in the prophylaxis group was investigated as a function of the duration of IPD® administration prior to the start of pollen dispersion, the good + excellent inhibition rate was 57.7% in the subpopulation pretreated for <2 weeks (26 cases), 64.9% with 2 to <4 weeks' pretreatment (37 cases) and 85.7% with 4 to <6 weeks' pretreatment (7 cases). Thus, IPD®'s prophylactic inhibitory rate increased with the length of the pretreatment period. (4) In the prophylaxis groups, the CAP-RAST value was significantly reduced at the time of peak pollen level and at the end of the pollen season compared with the value before IPD® administration.